Table of Contents Author Guidelines Submit a Manuscript
Journal of Nanomaterials
Volume 2016, Article ID 5436458, 16 pages
http://dx.doi.org/10.1155/2016/5436458
Review Article

What Is the Role of Nanotechnology in Diagnosis and Treatment of Metastatic Breast Cancer? Promising Scenarios for the Near Future

1Department of Biomedical and Clinical Sciences “L. Sacco”, University of Milan, Via G. B. Grassi 74, 20157 Milan, Italy
2Surgery Division, “Luigi Sacco” Hospital, Via G. B. Grassi 74, 20157 Milan, Italy

Received 30 March 2016; Accepted 22 May 2016

Academic Editor: Michele Laus

Copyright © 2016 Truffi Marta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. DeSantis, J. Ma, L. Bryan, and A. Jemal, “Breast cancer statistics, 2013,” CA: A Cancer Journal for Clinicians, vol. 64, no. 1, pp. 52–62, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Glück, F. de Snoo, J. Peeters, L. Stork-Sloots, and G. Somlo, “Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy,” Breast Cancer Research and Treatment, vol. 139, no. 3, pp. 759–767, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. Cancer Genome Atlas Network, “Comprehensive molecular portraits of human breast tumours,” Nature, vol. 490, no. 7418, pp. 61–70, 2012. View at Publisher · View at Google Scholar
  4. B. Fisher, J. Costantino, C. Redmond et al., “A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors,” The New England Journal of Medicine, vol. 320, no. 8, pp. 479–484, 1989. View at Publisher · View at Google Scholar · View at Scopus
  5. E. M. Olson, J. S. Najita, J. Sohl et al., “Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era,” The Breast, vol. 22, no. 4, pp. 525–531, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. D. M. Gagliato, D. L. Jardim, M. S. Marchesi, and G. N. Hortobagyi, “Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer,” Oncotarget, 2016. View at Publisher · View at Google Scholar
  7. J. O'Shaughnessy, “Extending survival with chemotherapy in metastatic breast cancer,” Oncologist, vol. 10, supplement 3, pp. 20–29, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. F. J. Esteva, V. Valero, L. Pusztai, L. Boehnke-Michaud, A. U. Buzdar, and G. N. Hortobagyi, “Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond,” Oncologist, vol. 6, no. 2, pp. 133–146, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. R. P. A'Hern, I. E. Smith, and S. R. Ebbs, “Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens,” British Journal of Cancer, vol. 67, no. 4, pp. 801–805, 1993. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Ghersi, M. L. Willson, M. M. K. Chan, J. Simes, E. Donoghue, and N. Wilcken, “Taxane-containing regimens for metastatic breast cancer,” Cochrane Database of Systematic Reviews, no. 6, Article ID CD003366, 2015. View at Publisher · View at Google Scholar
  11. K. Shan, A. M. Lincoff, and J. B. Young, “Anthracycline-induced cardiotoxicity,” Annals of Internal Medicine, vol. 125, no. 1, pp. 47–58, 1996. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Schroeder, D. A. Heller, M. M. Winslow et al., “Treating metastatic cancer with nanotechnology,” Nature Reviews Cancer, vol. 12, no. 1, pp. 39–50, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Tanaka, P. Decuzzi, M. Cristofanilli et al., “Nanotechnology for breast cancer therapy,” Biomedical Microdevices, vol. 11, no. 1, pp. 49–63, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. S. T. Duggan, G. M. Keating, G. Ferrandina, J. P. Kesterson, D. Lorusso, and F. Muggia, “Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposis sarcoma,” Drugs, vol. 71, no. 18, pp. 2531–2558, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. M. E. R. O'Brien, N. Wigler, M. Inbar et al., “Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer,” Annals of Oncology, vol. 15, no. 3, pp. 440–449, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. T. M. Allen, C. Hansen, F. Martin, C. Redemann, and A. Yau-Young, “Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo,” Biochimica et Biophysica Acta (BBA)—Biomembranes, vol. 1066, no. 1, pp. 29–36, 1991. View at Publisher · View at Google Scholar · View at Scopus
  17. C. K. Anders, B. Adamo, O. Karginova et al., “Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer,” PLoS ONE, vol. 8, no. 5, Article ID e61359, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Harris, G. Batist, R. Belt et al., “Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma,” Cancer, vol. 94, no. 1, pp. 25–36, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Batist, G. Ramakrishnan, C. S. Rao et al., “Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer,” Journal of Clinical Oncology, vol. 19, no. 5, pp. 1444–1454, 2001. View at Google Scholar · View at Scopus
  20. S. Chan, N. Davidson, E. Juozaityte et al., “Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer,” Annals of Oncology, vol. 15, no. 10, pp. 1527–1534, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Megerdichian, Y. Olimpiadi, and S. A. Hurvitz, “Nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer,” Cancer Treatment Reviews, vol. 40, no. 5, pp. 614–625, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Glück, “nab-Paclitaxel for the treatment of aggressive metastatic breast cancer,” Clinical Breast Cancer, vol. 14, no. 4, pp. 221–227, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. W. J. Gradishar, S. Tjulandin, N. Davidson et al., “Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer,” Journal of Clinical Oncology, vol. 23, no. 31, pp. 7794–7803, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. W. J. Gradishar, D. Krasnojon, S. Cheporov et al., “Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer,” Journal of Clinical Oncology, vol. 27, no. 22, pp. 3611–3619, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Lobo, G. Lopes, O. Baez et al., “Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer,” Breast Cancer Research and Treatment, vol. 123, no. 2, pp. 427–435, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. H. S. Rugo, W. T. Barry, A. Moreno-Aspitia et al., “Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance),” Journal of Clinical Oncology, vol. 33, no. 21, pp. 2361–2369, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. K. J. O'Byrne, A. L. Thomas, R. A. Sharma et al., “A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer,” British Journal of Cancer, vol. 87, no. 1, pp. 15–20, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Awada, I. N. Bondarenko, J. Bonneterre et al., “A randomized controlled phase ii trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (tnbc),” Annals of Oncology, vol. 25, no. 4, pp. 824–831, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. K. S. Lee, H. C. Chung, S. A. Im et al., “Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer,” Breast Cancer Research and Treatment, vol. 108, no. 2, pp. 241–250, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Rai, R. Paliwal, and S. P. Vyas, “Doxorubicin encapsulated nanocarriers for targeted delivery to estrogen responsive breast cancer,” Journal of Biomedical Nanotechnology, vol. 7, no. 1, pp. 121–122, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. T. A. Elbayoumi and V. P. Torchilin, “Tumor-specific antibody-mediated targeted delivery of Doxil® reduces the manifestation of auricular erythema side effect in mice,” International Journal of Pharmaceutics, vol. 357, no. 1-2, pp. 272–279, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Lu, S.-B. Xiong, H. Yang, X.-D. Yin, and R.-B. Chao, “Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases,” European Journal of Pharmaceutical Sciences, vol. 28, no. 1-2, pp. 86–95, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. P. P. Karmali, V. R. Kotamraju, M. Kastantin et al., “Targeting of albumin-embedded paclitaxel nanoparticles to tumors,” Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 5, no. 1, pp. 73–82, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Li, Z. Shen, X. Ma et al., “Neuropeptide Y Y1 receptors meditate targeted delivery of anticancer drug with encapsulated nanoparticles to breast cancer cells with high selectivity and its potential for breast cancer therapy,” ACS Applied Materials and Interfaces, vol. 7, no. 9, pp. 5574–5582, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. L. M. Kaminskas, V. M. McLeod, G. M. Ryan et al., “Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy,” Journal of Controlled Release, vol. 183, no. 1, pp. 18–26, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. V. Elazar, H. Adwan, T. Bäuerle, K. Rohekar, G. Golomb, and M. R. Berger, “Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis,” International Journal of Cancer, vol. 126, no. 7, pp. 1749–1760, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Reufsteck, R. Lifshitz-Shovali, M. Zepp et al., “Silencing of skeletal metastasis-associated genes impairs migration of breast cancer cells and reduces osteolytic bone lesions,” Clinical and Experimental Metastasis, vol. 29, no. 5, pp. 441–456, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Cao, Z. Zhang, S. Zhao et al., “Hydrophobic interaction mediating self-assembled nanoparticles of succinobucol suppress lung metastasis of breast cancer by inhibition of VCAM-1 expression,” Journal of Controlled Release, vol. 205, pp. 162–171, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Devulapally, N. M. Sekar, T. V. Sekar et al., “Polymer nanoparticles mediated codelivery of AntimiR-10b and AntimiR-21 for achieving triple negative breast cancer therapy,” ACS Nano, vol. 9, no. 3, pp. 2290–2302, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. S. I. Thamake, S. L. Raut, Z. Gryczynski, A. P. Ranjan, and J. K. Vishwanatha, “Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer,” Biomaterials, vol. 33, no. 29, pp. 7164–7173, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. R. Paulmurugan, R. Bhethanabotla, K. Mishra et al., “Folate receptor-targeted polymeric micellar nanocarriers for delivery of orlistat as a repurposed drug against triple-negative breast cancer,” Molecular Cancer Therapeutics, vol. 15, no. 2, pp. 221–231, 2016. View at Publisher · View at Google Scholar
  42. J. Li, P. Cai, A. Shalviri et al., “A multifunctional polymeric nanotheranostic system delivers doxorubicin and imaging agents across the blood-brain barrier targeting brain metastases of breast cancer,” ACS Nano, vol. 8, no. 10, pp. 9925–9940, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Patil, A. V. Ljubimov, P. R. Gangalum et al., “MRI virtual biopsy and treatment of brain metastatic tumors with targeted nanobioconjugates: nanoclinic in the brain,” ACS Nano, vol. 9, no. 5, pp. 5594–5608, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. A. P. Mann, T. Tanaka, A. Somasunderam, X. Liu, D. G. Gorenstein, and M. Ferrari, “E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow,” Advanced Materials, vol. 23, no. 36, pp. H278–H282, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. F. Dilnawaz, A. Singh, C. Mohanty, and S. K. Sahoo, “Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy,” Biomaterials, vol. 31, no. 13, pp. 3694–3706, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. P. M. Peiris, R. Toy, A. Abramowski et al., “Treatment of cancer micrometastasis using a multicomponent chain-like nanoparticle,” Journal of Controlled Release, vol. 173, no. 1, pp. 51–58, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. W. I. Choi, J. H. Lee, J.-Y. Kim et al., “Targeted antitumor efficacy and imaging via multifunctional nano-carrier conjugated with anti-HER2 trastuzumab,” Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 11, no. 2, pp. 359–368, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. P. M. Peiris, R. Toy, E. Doolittle et al., “Imaging metastasis using an integrin-targeting chain-shaped nanoparticle,” ACS Nano, vol. 6, no. 10, pp. 8783–8795, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. H. B. Na, J. H. Lee, K. An et al., “Development of a T1 contrast agent for magnetic resonance imaging using MnO nanoparticles,” Angewandte Chemie—International Edition, vol. 46, no. 28, pp. 5397–5401, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Bardhan, W. Chen, M. Bartels et al., “Tracking of multimodal therapeutic nanocomplexes targeting breast cancer in vivo,” Nano Letters, vol. 10, no. 12, pp. 4920–4928, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. C. Leuschner, C. S. S. R. Kumar, W. Hansel, W. Soboyejo, J. Zhou, and J. Hormes, “LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases,” Breast Cancer Research and Treatment, vol. 99, no. 2, pp. 163–176, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Meng, J. Fan, G. Galiana et al., “LHRH-functionalized superparamagnetic iron oxide nanoparticles for breast cancer targeting and contrast enhancement in MRI,” Materials Science and Engineering C, vol. 29, no. 4, pp. 1467–1479, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. B. Pang, Y. Zhao, H. Luehmann et al., “64Cu-doped PdCu@Au tripods: a multifunctional nanomaterial for positron emission tomography and image-guided photothermal cancer treatment,” ACS Nano, vol. 10, no. 3, pp. 3121–3131, 2016. View at Publisher · View at Google Scholar
  54. L. Yang, X.-H. Peng, Y. A. Wang et al., “Receptor-targeted nanoparticles for in vivo imaging of breast cancer,” Clinical Cancer Research, vol. 15, no. 14, pp. 4722–4732, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. E. I. Galanzha, J.-W. Kim, and V. P. Zharov, “Nanotechnology-based molecular photoacoustic and photothermal flow cytometry platform for in-vivo detection and killing of circulating cancer stem cells,” Journal of Biophotonics, vol. 2, no. 12, pp. 725–735, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. F. Chen, T. R. Nayak, S. Goel et al., “In vivo tumor vasculature targeted PET/NIRF imaging with TRC105(Fab)-conjugated, dual-labeled mesoporous silica nanoparticles,” Molecular Pharmaceutics, vol. 11, no. 11, pp. 4007–4014, 2014. View at Publisher · View at Google Scholar
  57. C. Pérez-Medina, J. Tang, D. Abdel-Atti et al., “PET imaging of tumor-associated macrophages with 89Zr-labeled high-density lipoprotein nanoparticles,” Journal of Nuclear Medicine, vol. 56, no. 8, pp. 1272–1277, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. J. Key, Y.-S. Kim, F. Tatulli et al., “Opportunities for nanotheranosis in lung cancer and pulmonary metastasis,” Clinical and Translational Imaging, vol. 2, no. 5, pp. 427–437, 2014. View at Publisher · View at Google Scholar
  59. M. Asadian-Birjand, C. Biglione, J. Bergueiro et al., “Transferrin decorated thermoresponsive nanogels as magnetic trap devices for circulating tumor cells,” Macromolecular Rapid Communications, vol. 37, no. 5, pp. 439–445, 2016. View at Publisher · View at Google Scholar
  60. F. M. Kievit, Z. R. Stephen, O. Veiseh et al., “Targeting of primary breast cancers and metastases in a transgenic mouse model using rationally designed multifunctional SPIONs,” ACS Nano, vol. 6, no. 3, pp. 2591–2601, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. T.-J. Chen, T.-H. Cheng, C.-Y. Chen et al., “Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI,” Journal of Biological Inorganic Chemistry, vol. 14, no. 2, pp. 253–260, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. A. MaHam, Z. Tang, H. Wu, J. Wang, and Y. Lin, “Protein-based nanomedicine platforms for drug delivery,” Small, vol. 5, no. 15, pp. 1706–1721, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. R. Duncan, “Polymer conjugates as anticancer nanomedicines,” Nature Reviews Cancer, vol. 6, no. 9, pp. 688–701, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. R. Fanciullino, J. Ciccolini, and G. Milano, “Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs,” Critical Reviews in Oncology/Hematology, vol. 88, no. 3, pp. 504–513, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. P. Zarogoulidis, E. Chatzaki, K. Porpodis et al., “Inhaled chemotherapy in lung cancer: future concept of nanomedicine,” International Journal of Nanomedicine, vol. 7, pp. 1551–1572, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. D. C. Drummond, O. Meyer, K. Hong, D. B. Kirpotin, and D. Papahadjopoulos, “Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors,” Pharmacological Reviews, vol. 51, no. 4, pp. 691–743, 1999. View at Google Scholar · View at Scopus
  67. A. Z. Wang, R. Langer, and O. C. Farokhzad, “Nanoparticle delivery of cancer drugs,” Annual Review of Medicine, vol. 63, pp. 185–198, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. M. J. Hawkins, P. Soon-Shiong, and N. Desai, “Protein nanoparticles as drug carriers in clinical medicine,” Advanced Drug Delivery Reviews, vol. 60, no. 8, pp. 876–885, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. D. A. Yardley, “Nab-Paclitaxel mechanisms of action and delivery,” Journal of Controlled Release, vol. 170, no. 3, pp. 365–372, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. P. Kesharwani and A. K. Iyer, “Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery,” Drug Discovery Today, vol. 20, no. 5, pp. 536–547, 2015. View at Publisher · View at Google Scholar · View at Scopus
  71. F. Corsi and S. Mazzucchelli, “The potential of protein-based nanocages for imaging and drug delivery,” Therapeutic Delivery, vol. 7, no. 3, pp. 149–151, 2016. View at Publisher · View at Google Scholar
  72. M. Truffi, L. Fiandra, L. Sorrentino, M. Monieri, F. Corsi, and S. Mazzucchelli, “Ferritin nanocages: a biological platform for drug delivery, imaging and theranostics in cancer,” Pharmacological Research, vol. 107, pp. 57–65, 2016. View at Publisher · View at Google Scholar
  73. G. Kore, A. Kolate, A. Nej, and A. Misra, “Polymeric micelle as multifunctional pharmaceutical carriers,” Journal of Nanoscience and Nanotechnology, vol. 14, no. 1, pp. 288–307, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. E. Rivera, “Current status of liposomal anthracycline therapy in metastatic breast cancer,” Clinical Breast Cancer, vol. 4, no. 2, pp. S76–S83, 2003. View at Publisher · View at Google Scholar · View at Scopus
  75. E. C. van Dalen, E. M. C. Michiels, H. N. Caron, and L. C. M. Kremer, “Different anthracycline derivates for reducing cardiotoxicity in cancer patients,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD005006, 2006. View at Google Scholar · View at Scopus
  76. G. Batist, J. Barton, P. Chaikin, C. Swenson, and L. Welles, “Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy,” Expert Opinion on Pharmacotherapy, vol. 3, no. 12, pp. 1739–1751, 2002. View at Publisher · View at Google Scholar · View at Scopus
  77. J. Liebmann, J. A. Cook, and J. B. Mitchell, “Cremophor EL, solvent for paclitaxel, and toxicity,” The Lancet, vol. 342, no. 8884, p. 1428, 1993. View at Publisher · View at Google Scholar · View at Scopus
  78. F. Muggia and D. Kudlowitz, “Novel taxanes,” Anti-Cancer Drugs, vol. 25, no. 5, pp. 593–598, 2014. View at Publisher · View at Google Scholar · View at Scopus
  79. N. Bertrand, J. Wu, X. Xu, N. Kamaly, and O. C. Farokhzad, “Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology,” Advanced Drug Delivery Reviews, vol. 66, pp. 2–25, 2014. View at Publisher · View at Google Scholar · View at Scopus
  80. T. Lammers, F. Kiessling, W. E. Hennink, and G. Storm, “Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress,” Journal of Controlled Release, vol. 161, no. 2, pp. 175–187, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. T. Lôrincz, J. Tímár, and M. Szendroi, “Alterations of microvascular density in bone metastases of adenocarcinomas,” Pathology and Oncology Research, vol. 10, no. 3, pp. 149–153, 2004. View at Publisher · View at Google Scholar · View at Scopus
  82. D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, and R. Langer, “Nanocarriers as an emerging platform for cancer therapy,” Nature Nanotechnology, vol. 2, no. 12, pp. 751–760, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. T. Sørlie, C. M. Perou, R. Tibshirani et al., “Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 19, pp. 10869–10874, 2001. View at Publisher · View at Google Scholar · View at Scopus
  84. D. Slamon, W. Eiermann, N. Robert et al., “Adjuvant trastuzumab in HER2-positive breast cancer,” The New England Journal of Medicine, vol. 365, no. 14, pp. 1273–1283, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. M. Colombo, F. Corsi, D. Foschi et al., “HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: outlook and recent implications in nanomedical approaches,” Pharmacological Research, vol. 62, no. 2, pp. 150–165, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. S. Sommaruga, A. Lombardi, A. Salvadè et al., “Highly efficient production of anti-HER2 scFv antibody variant for targeting breast cancer cells,” Applied Microbiology and Biotechnology, vol. 91, no. 3, pp. 613–621, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. L. Fiandra, S. Mazzucchelli, C. De Palma et al., “Assessing the in vivo targeting efficiency of multifunctional nanoconstructs bearing antibody-derived ligands,” ACS Nano, vol. 7, no. 7, pp. 6092–6102, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. F. Corsi, L. Fiandra, C. De Palma et al., “HER2 expression in breast cancer cells is downregulated upon active targeting by antibody-engineered multifunctional nanoparticles in mice,” ACS Nano, vol. 5, no. 8, pp. 6383–6393, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. S. Mazzucchelli, M. Truffi, L. Fiandra, L. Sorrentino, and F. Corsi, “Targeted approaches for HER2 breast cancer therapy: news from nanomedicine?” World Journal of Pharmacology, vol. 3, no. 4, pp. 72–85, 2014. View at Publisher · View at Google Scholar
  90. Y. Lu and P. S. Low, “Folate-mediated delivery of macromolecular anticancer therapeutic agents,” Advanced Drug Delivery Reviews, vol. 54, no. 5, pp. 675–693, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. Z. M. Qian, H. Li, H. Sun, and K. Ho, “Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway,” Pharmacological Reviews, vol. 54, no. 4, pp. 561–587, 2002. View at Publisher · View at Google Scholar · View at Scopus
  92. M. P. Melancon, W. Lu, Z. Yang et al., “In vitro and in vivo targeting of hollow gold nanoshells directed at epidermal growth factor receptor for photothermal ablation therapy,” Molecular Cancer Therapeutics, vol. 7, no. 6, pp. 1730–1739, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. A. M. Le Beau, S. Duriseti, S. T. Murphy et al., “Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer,” Cancer Research, vol. 73, no. 7, pp. 2070–2081, 2013. View at Publisher · View at Google Scholar · View at Scopus
  94. D. Neri and R. Bicknell, “Tumour vascular targeting,” Nature Reviews Cancer, vol. 5, no. 6, pp. 436–446, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. T. Lammers, F. Kiessling, W. E. Hennink, and G. Storm, “Nanotheranostics and image-guided drug delivery: current concepts and future directions,” Molecular Pharmaceutics, vol. 7, no. 6, pp. 1899–1912, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. L. Borsi, E. Balza, M. Bestagno et al., “Selective targeting of tumoral vasculature: comparison of different formats of an antibody (l19) to the ED-B domain of fibronectin,” International Journal of Cancer, vol. 102, no. 1, pp. 75–85, 2002. View at Publisher · View at Google Scholar · View at Scopus
  97. A. Mitra, J. Mulholland, A. Nan, E. McNeill, H. Ghandehari, and B. R. Line, “Targeting tumor angiogenic vasculature using polymer-RGD conjugates,” Journal of Controlled Release, vol. 102, no. 1, pp. 191–201, 2005. View at Publisher · View at Google Scholar · View at Scopus
  98. T. Lorincz, J. Tóth, G. Badalian, J. Tímár, and M. Szendroi, “HER-2/neu genotype of breast cancer may change in bone metastasis,” Pathology and Oncology Research, vol. 12, no. 3, pp. 149–152, 2006. View at Publisher · View at Google Scholar · View at Scopus
  99. Z. Gabos, R. Sinha, J. Hanson et al., “Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer,” Journal of Clinical Oncology, vol. 24, no. 36, pp. 5658–5663, 2006. View at Publisher · View at Google Scholar · View at Scopus
  100. J. Hu and S. Kesari, “Strategies for overcoming the blood-brain barrier for the treatment of brain metastases,” CNS Oncology, vol. 2, no. 1, pp. 87–98, 2013. View at Publisher · View at Google Scholar · View at Scopus
  101. M. Caraglia, G. De Rosa, G. Salzano et al., “Nanotech revolution for the anti-cancer drug delivery through blood-brain-barrier,” Current Cancer Drug Targets, vol. 12, no. 3, pp. 186–196, 2012. View at Publisher · View at Google Scholar · View at Scopus
  102. C. Cao, X. Wang, Y. Cai et al., “Targeted in vivo imaging of microscopic tumors with ferritin-based nanoprobes across biological barriers,” Advanced Materials, vol. 26, no. 16, pp. 2566–2571, 2014. View at Publisher · View at Google Scholar · View at Scopus
  103. K. Michaelis, M. M. Hoffmann, S. Dreis et al., “Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain,” Journal of Pharmacology and Experimental Therapeutics, vol. 317, no. 3, pp. 1246–1253, 2006. View at Publisher · View at Google Scholar · View at Scopus
  104. G. R. Mundy, “Metastasis to bone: causes, consequences and therapeutic opportunities,” Nature Reviews Cancer, vol. 2, no. 8, pp. 584–593, 2002. View at Publisher · View at Google Scholar · View at Scopus
  105. P. Clézardin, “Therapeutic targets for bone metastases in breast cancer,” Breast Cancer Research, vol. 13, no. 2, article 207, 2011. View at Publisher · View at Google Scholar · View at Scopus
  106. N. Bednarz-Knoll, C. Alix-Panabières, and K. Pantel, “Clinical relevance and biology of circulating tumor cells,” Breast Cancer Research, vol. 13, no. 6, article 228, 2011. View at Publisher · View at Google Scholar · View at Scopus
  107. K. Pantel, C. Alix-Panabières, and S. Riethdorf, “Cancer micrometastases,” Nature Reviews Clinical Oncology, vol. 6, no. 6, pp. 339–351, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. M. Ahmed and M. Douek, “The role of magnetic nanoparticles in the localization and treatment of breast cancer,” BioMed Research International, vol. 2013, Article ID 281230, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  109. B. E. Dogan and L. W. Turnbull, “Imaging of triple-negative breast cancer,” Annals of Oncology, vol. 23, supplement 6, pp. vi23–vi29, 2012. View at Google Scholar